Hospital Pathology Associates, 2800 10th Avenue South, Suite 2200, Minneapolis, MN 55407, USA.
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Surg Pathol Clin. 2023 Jun;16(2):401-410. doi: 10.1016/j.path.2023.01.005. Epub 2023 Mar 10.
Genetic characterization of myeloma at diagnosis by interphase fluorescence in situ hybridization and next-generation sequencing (NGS) can assist with risk stratification and treatment planning. Measurable residual disease (MRD) status after treatment, as evaluated by next-generation flow cytometry or NGS on bone marrow aspirate material, is one of the most important predictors of prognosis. Less-invasive tools for MRD assessment such as liquid biopsy approaches have also recently emerged as potential alternatives.
通过间期荧光原位杂交和下一代测序 (NGS) 对骨髓瘤进行诊断时的基因特征分析有助于风险分层和治疗计划。通过下一代流式细胞术或骨髓抽吸物的 NGS 评估的治疗后可测量残留疾病 (MRD) 状态是预后的最重要预测指标之一。最近，液体活检等用于 MRD 评估的微创工具也作为潜在的替代方法出现。
Zotero 插件